This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|March 13, 2018
USP Cancels Revisions to Packaging Chapters
Author(s)Pharmaceutical Technology Editors
Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.
Advertisement
In an online posting on Feb. 23. 2018, USP announced the cancellation of revisions to packaging-related general chapters pending “comprehensive and strategic redevelopment” following comments received on the proposed revisions.
The affected chapters, which were published for comment in Pharmacopeial Forum 43(3) [May–Jun. 2017], are as follows:
- <660> Containers-Glass
- <1660> Evaluation of the Inner Surface Durability of Glass Containers
- <381> Elastomeric Closure for Injections
- <382> Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery Systems
- <1381> Elastomeric Evaluation of Elastomeric Components Used in Pharmaceutical Packaging/Delivery Systems
- <1382> Assessment of Elastomeric Closure Functionality in Injectable Pharmaceutical Packaging/Delivery
USP noted that the revisions will appear on the Cancellations list for the Second Supplement to USP 41–NF 36, which will be posted on April 27, 2018. USP anticipates that it will publish revised proposals for the affected General Chapters in a future issue of the Pharmacopeial Forum.
Source:
Advertisement
Related to this article
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
3
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
4
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
5